fbpx

News

Lundbeckfonden Ventures News

SAN DIEGO, Feb. 27, 2014 (GLOBE NEWSWIRE) — Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, announced today the full exercise and closing of the underwriters' option to purchase 825,000 additional shares of common stock in connection with Celladon's previously...
Servier Receives Exclusive Option to Enter Into Worldwide, Ex-U.S., Research Collaboration and License for Celladon's Novel Small Molecule SERCA2b Modulators for the Treatment of Diabetes and Metabolic Diseases
SAN DIEGO, CA, Thesan Pharmaceuticals announced today the closing of a $49M Series B financing, led by Novo Ventures (a current Investor), with SV Life Sciences and Lundbeckfond Ventures joining Novartis Venture Fund in the syndicate. Thesan’s mission is the development of novel approaches for the treatment of dermatological disorders, including acne and atopic dermatitis....
Lund, Sweden, (PRNEWSWIRE) February 18, 2014 – BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced today the launch of a new registry to collect long term data of CERAMENTT’G, the first injectable antibiotic eluting, osteoconductive, ceramic bone substitute indicated to promote and...
Today only an average of 50% of stroke survivors recovers full use of their arm. A study from the Rehabilitation Institute of Chicago approached stroke rehabilitation through a new combination of therapies which produced significantly greater gains in their motor function 6 months post stroke. The series of combination therapy used non-invasive navigated transcranial stimulation...
SAN DIEGO, CA, January 29, 2014 – Celladon Corporation (NASDAQ: CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, announced today the pricing of its initial public offering of 5,500,000 shares of its common stock at $8.00 per share. Celladon has also granted...
Edinburgh – 7 January 2014 ? DySIS Medical Ltd, a medical devices company active within Women’s Health, today announces that Robert Cascella has joined as Chairman of the board of directors of the Company effective January 2014. His appointment further strengthens the board following a year of investment and growth in 2013. Mr. Cascella was...
BAGNEUX, France, Dec. 17, 2013 – DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new paradigm for the treatment of allergies, announced today a summary of corporate activities in 2013 and provided news flow guidance for 2014. Dr. Pierre-Henri Benhamou, Chairman & CEO of DBV Technologies, said: It has been an extremely...
DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new paradigm for the treatment of allergies, announced today the presentation of Epicutaneous Immunotherapy for Food Allergy” at a meeting of the World Allergy Organization by Dr. Hugh Sampson, Kurt Hisrchhorn Professor of Pediatrics, Director of the Jaffe Food Allergy Institute and Dean of...
1 43 44 45 46 47 58

Lundbeckfonden Ventures

News

BONESUPPORT HOLDING AB (publ) – Q2 2019 Interim Report – invitation to conference call and webcast
18. July 2019
Acacia Pharma Group PLC – Acacia Pharma Founder Dr. Julian Gilbert steps down – Michael Bolinder, Chief Commercial Officer, becomes CEO in Planned Succession
18. July 2019
scPharmaceuticals Inc. Provides Regulatory Update on FUROSCIX®
16. July 2019